JP2024523034A - 二重特異性抗ｃｃｌ２抗体 - Google Patents

二重特異性抗ｃｃｌ２抗体 Download PDF

Info

Publication number
JP2024523034A
JP2024523034A JP2023577644A JP2023577644A JP2024523034A JP 2024523034 A JP2024523034 A JP 2024523034A JP 2023577644 A JP2023577644 A JP 2023577644A JP 2023577644 A JP2023577644 A JP 2023577644A JP 2024523034 A JP2024523034 A JP 2024523034A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
domain comprises
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577644A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523034A5 (enExample
Inventor
ベルティネッティ－ラパトゥキ，クリスティーナ
フェン，シュウ
フィッシャー，イェンス
ガン，シオク・ワン
ジョルジュ，ギー
ゲルツ，ミヒャエル
ホ，ウェイ・シオン・エイドリアン
カスプシク，ウカシュ
ラム，ルンイ・アデリーン
ランザ，ヴァレリア
シドー－アンデルセン，ジャスミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2024523034A publication Critical patent/JP2024523034A/ja
Publication of JP2024523034A5 publication Critical patent/JP2024523034A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023577644A 2021-06-18 2022-06-15 二重特異性抗ｃｃｌ２抗体 Pending JP2024523034A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21180204.6 2021-06-18
EP21180204 2021-06-18
PCT/EP2022/066289 WO2022263501A1 (en) 2021-06-18 2022-06-15 Bispecific anti-ccl2 antibodies

Publications (2)

Publication Number Publication Date
JP2024523034A true JP2024523034A (ja) 2024-06-25
JP2024523034A5 JP2024523034A5 (enExample) 2025-06-09

Family

ID=76522859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577644A Pending JP2024523034A (ja) 2021-06-18 2022-06-15 二重特異性抗ｃｃｌ２抗体

Country Status (8)

Country Link
US (1) US20240360208A1 (enExample)
EP (1) EP4355775A1 (enExample)
JP (1) JP2024523034A (enExample)
KR (1) KR20240021859A (enExample)
CN (1) CN117500829A (enExample)
AU (1) AU2022295067A1 (enExample)
CA (1) CA3221735A1 (enExample)
WO (1) WO2022263501A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026050531A1 (en) * 2024-08-28 2026-03-05 New York University Aneuploidy-associated drug targets in lung cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005536534A (ja) * 2002-08-19 2005-12-02 アブジェニックス・インコーポレーテッド 単球走化性タンパク質−１（ｍｃｐ−１）に対する抗体、およびその使用
JP2008546374A (ja) * 2005-05-19 2008-12-25 セントカー・インコーポレーテツド 抗ｍｃｐ−１抗体、組成物、方法および使用
JP2011517548A (ja) * 2007-06-29 2011-06-16 セントコア・オーソ・バイオテツク・インコーポレーテツド 抗ｍｃｐ−１抗体、組成物、方法及び使用
JP2015522246A (ja) * 2012-03-27 2015-08-06 ジェネンテック， インコーポレイテッド 特発性肺線維症の予後予測、診断および処置の方法
JP2016520594A (ja) * 2013-05-23 2016-07-14 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 強皮症治療のための抗ｃｃｌ２及び抗ｌｏｘｌ２併用療法
JP7415005B2 (ja) * 2019-12-18 2024-01-16 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ｃｃｌ２抗体

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
ATE480562T1 (de) 2002-10-15 2010-09-15 Facet Biotech Corp Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
EP3342782B1 (en) 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2585891A1 (en) 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
ATE423140T1 (de) 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
RS53263B (sr) 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
US20080044455A1 (en) 2006-08-21 2008-02-21 Chaim Welczer Tonsillitus Treatment
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
AU2007337983A1 (en) * 2006-12-22 2008-07-03 Ablynx N.V. Anti-chemokine (CCL2, CCL3, CCL5, CXCL11, CXCL12) single-domain antibodies
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
KR101616758B1 (ko) 2007-12-26 2016-04-29 젠코어 인코포레이티드 ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
AU2009303526B2 (en) 2008-10-14 2015-01-15 Genentech, Inc. Immunoglobulin variants and uses thereof
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
SG176219A1 (en) 2009-05-27 2011-12-29 Hoffmann La Roche Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CN102712696A (zh) 2009-09-16 2012-10-03 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
EP2598530A2 (en) 2010-07-29 2013-06-05 Xencor, Inc. Antibodies with modified isoelectric points
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
WO2012132067A1 (ja) 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
JP6026441B2 (ja) 2011-03-04 2016-11-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのアミノキノリン
KR101721301B1 (ko) 2011-08-23 2017-03-29 로슈 글리카트 아게 이중특이적 항원 결합 분자
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
CN107287660A (zh) 2011-09-30 2017-10-24 中外制药株式会社 离子浓度依赖性结合分子文库
KR20250078601A (ko) 2011-09-30 2025-06-02 추가이 세이야쿠 가부시키가이샤 항원의 소실을 촉진시키는 항원 결합 분자
KR20210074395A (ko) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
CA2865158C (en) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
JPWO2013180201A1 (ja) 2012-05-30 2016-01-21 中外製薬株式会社 会合化した抗原を消失させる抗原結合分子
WO2013180200A1 (ja) 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
WO2014145159A2 (en) 2013-03-15 2014-09-18 Permeon Biologics, Inc. Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
BR112016011027A2 (pt) 2013-12-20 2017-12-05 Genentech Inc método de produção de um anticorpo, anticorpos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, método de tratamento de asma e método de tratamento de um distúrbio
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
EP3174897B1 (en) 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Multispecific antibodies
MX2017005774A (es) * 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
CA2980189A1 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
PE20181336A1 (es) 2015-09-18 2018-08-21 Chugai Pharmaceutical Co Ltd Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
JP2021526026A (ja) 2018-06-08 2021-09-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 翻訳後修飾が低減したペプチドリンカー

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005536534A (ja) * 2002-08-19 2005-12-02 アブジェニックス・インコーポレーテッド 単球走化性タンパク質−１（ｍｃｐ−１）に対する抗体、およびその使用
JP2008546374A (ja) * 2005-05-19 2008-12-25 セントカー・インコーポレーテツド 抗ｍｃｐ−１抗体、組成物、方法および使用
JP2011517548A (ja) * 2007-06-29 2011-06-16 セントコア・オーソ・バイオテツク・インコーポレーテツド 抗ｍｃｐ−１抗体、組成物、方法及び使用
JP2015522246A (ja) * 2012-03-27 2015-08-06 ジェネンテック， インコーポレイテッド 特発性肺線維症の予後予測、診断および処置の方法
JP2016520594A (ja) * 2013-05-23 2016-07-14 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 強皮症治療のための抗ｃｃｌ２及び抗ｌｏｘｌ２併用療法
JP7415005B2 (ja) * 2019-12-18 2024-01-16 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ｃｃｌ２抗体

Also Published As

Publication number Publication date
AU2022295067A1 (en) 2023-12-21
US20240360208A1 (en) 2024-10-31
CA3221735A1 (en) 2022-12-22
EP4355775A1 (en) 2024-04-24
WO2022263501A1 (en) 2022-12-22
AU2022295067A9 (en) 2024-01-11
KR20240021859A (ko) 2024-02-19
CN117500829A (zh) 2024-02-02

Similar Documents

Publication Publication Date Title
US11365261B2 (en) Anti-CD38 antibodies and methods of use
KR102720337B1 (ko) Cd3에 결합하는 항체
JP6463522B2 (ja) Ａｓｇｐｒ抗体およびその使用
TWI837084B (zh) 促凝血抗體
US12630622B2 (en) Bispecific anti-CCL2 antibodies
US20240360208A1 (en) Bispecific anti-ccl2 antibodies
RU2819613C1 (ru) Биспецифические антитела к ccl2
HK40106100A (en) Bispecific anti-ccl2 antibodies
HK40077249A (en) Bispecific anti-ccl2 antibodies
RU2832669C2 (ru) Антитела, связывающиеся с cd3
US20260098100A1 (en) Il-4r and tslp inhibitors and methods of use thereof
HK40112237A (en) Bispecific anti-ccl2 antibodies
RU2841523C2 (ru) Антитела, связывающиеся с gprc5d
CN121816362A (zh) 结合白细胞介素13和tslp或tslpr的抗体及其使用方法
CN117136198A (zh) 激动性抗il-2r抗体及其使用方法
HK40066221B (en) Humanized anti-vegf fab antibody fragment and use thereof
HK40066221A (en) Humanized anti-vegf fab antibody fragment and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260427